Eliminating the laboratory step in cartilage repair

What a laboratory dependency actually cost patients

For patients seeking cartilage repair through established cell-culture-based procedures, the treatment pathway began with an operation that did not treat them at all.

Both ACI (Autologous Chondrocyte Implantation) and its second-generation variant MACI — each with a genuine evidence base for pain relief and cartilage restoration — share the same structural requirement: a first hospital admission, conducted under arthroscopy, in which a small cartilage biopsy is harvested from the patient's joint and dispatched to a specialist external laboratory. There, the chondrocytes are isolated through enzyme digestion and expanded in cell culture over several weeks before a second admission is arranged for the actual implantation. Two separate operations, two separate anaesthetics, and a waiting interval measured in weeks.

During that interval, no therapeutic intervention occurs. The patient leaves the first operation without treatment, returns home, and waits — while their cartilage sample moves through a chain that is expensive, manual, and outside the direct control of both the surgeon and the patient. Timing, cell yield, and tissue viability during this period depend on the external laboratory rather than the clinical team. For someone already managing joint pain and restricted function, the inter-admission gap compounds the clinical burden with logistical and, in many cases, financial weight.

This dependency on an off-site facility was not incidental to ACI and MACI — it was built into their architecture. Cell culture expansion was the mechanism by which sufficient cell numbers were generated for implantation. It was also, as a consequence, a structural bottleneck: a weeks-long pause woven into the middle of a single repair procedure, placing the process in, as one description puts it, 'everyone's hands but their own.' Understanding this design constraint is the starting point for understanding why NanoACi was built the way it was.

The decision to collapse two admissions into one sitting

The response to that bottleneck is structural. Professor Paul Lee designed NanoACi as a one-stage procedure that is surgeon-led, non-arthroscopic, and needle-delivered — built specifically to remove the external laboratory from the cartilage repair pathway entirely. Its full name encodes the decision: Non-Arthroscopic, Needle-delivered, One-stop Autologous Chondrogenic Injection.

In place of culture-based cell expansion, NanoACi substitutes mechanical preparation performed by the treating clinician in a single planned sitting. A small sample of auricular (ear) cartilage is processed at point of care using the Rigenera Autologous Micrografting Technology (AMT) system, which disaggregates the tissue mechanically — without enzyme digestion, without culture, and without dispatch to any external facility. The processed material, Mytocel MSK, becomes the biological seed of the procedure: autologous micrografts prepared in the same attendance and ready for use within it.

Two further components are combined in the same session. ChondroFiller, a cell-free native type I collagen scaffold, provides the structural matrix — the scaffold into which the micrografts are introduced. Arthrozheal, an autologous platelet-rich fibrin preparation, delivers the signal: a sustained growth-factor environment designed to support tissue repair. Seed, scaffold, signal: all three are assembled and delivered through a needle in approximately half an hour.

No laboratory. No second admission. No waiting period. As Professor Lee has described the guiding principle: 'The innovation is not something I added. The innovation is the surgery I took away.'

Why ear cartilage does not need culture-based reprogramming

Selecting the ear as the donor site was not a matter of surgical convenience. The choice reflects a biological distinction that directly enables the point-of-care approach described in the previous section.

Unlike the cartilage of the knee or hip — which derives from the mesoderm, the embryonic layer that gives rise to the limb skeleton — auricular cartilage develops from the neural crest. This difference in developmental origin has a practical consequence. Mesodermal cartilage cells carry HOX gene expression, which encodes positional identity: in effect, a cellular address that anchors the cell to its anatomical site of origin. Neural-crest-derived cells are HOX-negative. They carry no such fixed address.

Research from a Basel group indicates that this absence of positional coding translates into genuine environmental adaptability in adult human tissue. When adult human neural-crest-derived chondrocytes were placed in an articular joint environment, the evidence suggests the cells read their new surroundings and adopted a joint-appropriate identity — without prior laboratory reprogramming or culture-based conditioning to prepare them for the transition.

This is the biological reason, rather than a logistical shortcut, for which mechanical preparation is considered sufficient. Because ear-derived cells appear capable of responding to joint cues directly, they do not require the weeks of in-vitro conditioning that mesodermal chondrocytes might need to function in an unfamiliar environment. The tissue source and the preparation method are therefore co-designed: auricular cartilage's plasticity is what makes point-of-care mechanical disaggregation clinically rational, not merely practical.

The preparation sequence: what happens in the chair

Carried out in a specialist clinical setting, the NanoACi preparation begins not with a needle but with a brief auricular biopsy — a small sample of cartilage taken from the ear under local anaesthesia. The donor site is chosen for what it offers: a consistently accessible, reliable source of neural-crest-derived tissue at minimal discomfort to the patient, available without any separate admission or arthroscopic harvest.

That sample passes directly into the Rigenera AMT device, which performs controlled mechanical disaggregation through a defined-pore mesh. What emerges is Mytocel MSK: tissue fragments that retain their cellular architecture and extracellular matrix — not a cell suspension or a cultured monolayer, but structurally intact micrografts ready for immediate use within the same visit.

The three components are then combined in sequence. The micrografts are introduced into ChondroFiller, a CE-marked cell-free native type I collagen scaffold. Arthrozheal — the autologous platelet-rich fibrin drawn from the patient's own blood earlier in the sitting — is added to provide the growth-factor environment that supports the assembly. Once combined, the preparation is delivered to the target site through a needle under image guidance.

Specialist input governs each decision along this sequence. Imaging review and case selection precede preparation; delivery is directed by real-time imaging throughout. Needle access is the route into the joint. The clinical judgement — selection, sequencing, preparation, and guided delivery — is the procedure.

Component evidence versus combined-protocol proof

The individual components in NanoACi are not experimental. ChondroFiller has been assessed against microfracture in randomised trials, has been used across multiple joints for more than a decade, and has accumulated over 20,000 implantations. The scaffold-plus-cells pairing — ChondroFiller combined with a cellular preparation — has published clinical support specifically in end-stage knees, the most demanding application of the approach. Arthrozheal, the autologous platelet-rich fibrin, is supported by published evidence for its growth-factor release profile and collagen stimulation, including Lundquist et al. (2008) and Ågren et al. (Vox Sanguinis, 2014).

That body of component evidence does not transfer to the combined NanoACi protocol. Four levels are distinct: what the technique does as a matter of fact; what the evidence says about each component separately; what measured outcomes for the exact three-part protocol show; and what independent external validation exists. The first two levels are established. The third and fourth are not.

The combined protocol — ChondroFiller, Mytocel MSK, and Arthrozheal prepared and delivered together in a single sitting — has not been assessed as a unified intervention in a randomised controlled trial. NanoACi 100, a structured prospective programme collecting pre-agreed outcomes across 100 consecutive cases, is the designated mechanism for generating that data. Combined-protocol results will be reported when the dataset is complete.

What remains unknown and how suitability is determined

Two specific questions remain unanswered. First: how does the cellular yield from a point-of-care mechanical preparation compare quantitatively with the expanded cell counts produced by weeks of laboratory culture? That comparison has not been made directly, and the clinical significance of any difference in yield is not yet established. Second: how do long-term outcomes from the one-stage approach compare with ACI and MACI in a direct controlled comparison? No randomised trial has yet placed the full protocols alongside each other with pre-agreed endpoints.

Both are bounded unknowns — not a general question mark over the technique, but specific gaps with a structured response. NanoACi 100 is collecting the data needed to characterise the combined protocol's performance across a consecutive series; what it must ultimately demonstrate is durable functional improvement at the intervals where established procedures have their longest track records. If the prospective dataset shows that, the one-stage model will have an outcomes record of its own — not borrowed from its components, and not inferred from the procedures it was designed to replace.

Suitability for NanoACi is determined by specialist assessment, not by technique description. The non-arthroscopic lane is appropriate for particular patients: alignment, instability, mechanical pathology, the extent and location of cartilage loss, symptom pattern, prior treatment history, and patient goals all bear directly on whether it is the right choice in a given case. Imaging review and structured consultation establish that — not self-selection.

1. [1] Point-of-care testing. https://en.wikipedia.org/?curid=8713563 https://en.wikipedia.org/?curid=8713563